Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab versus obinutuzumab in systemic lupus erythematosus
NL-OMON59423Phase 4Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab and obinutuzumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Peripheral blood CD19-positive B-cell depletion and Lymph node CD19-positive B-cell depletion. Started Nov 2024; status: recruiting.
02
Drugs
rituximabobinutuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON59423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59423.